Evaluation of pulmonary function in workers exposed to hexamethylene diisocyanate.

Production of hexamethylene diisocyanate (HDI) biuret and trimer from HDI monomer was started in 1988 at the plant under study. Pulmonary function tests were included as part of the annual evaluation of the workers in that unit. HDI is expected to have toxic properties similar to those of toluene diisocyanate. The latter has caused accelerated declines in pulmonary function in exposed workers. In 1991, an initial longitudinal evaluation of those pulmonary function tests was performed, comparing annual declines in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1). The purpose of the study was to evaluate whether or not exposures to HDI at the unit had caused any accelerated decline in FVC or FEV1. No significant differences were seen in that evaluation, but it was decided that the study be continued in a prospective fashion. The study has been continued through 1997. The slope of the annual change in FVC and FEV1 were calculated for a group of workers and a matched control group. The average annual decline in FVC for the exposed group (cases) was 0.026 L, compared with 0.025 L for the control group. For the decline in FEV1, the results were 0.044 L, compared with 0.041 L (P = 0.79). These results are virtually identical and support a conclusion that exposures within this unit to HDI have not caused an accelerated decline in FVC or FEV1. Exposures to HDI were measured during this period. The time-weighted average exposure to HDI during work not requiring respiratory protection in the unit (approximately 2 hours per day) was 0.5 parts per billion. The average daily high peak exposure was 2.9 parts per billion. Exposure to these levels appear to pose no risk of accelerated decline in pulmonary function.